How much bacteriostatic water with tesamorelin?
Most research-handling protocols use 2 mL of bacteriostatic water per 10 mg tesamorelin vial, yielding a 5 mg/mL working concentration. Tesamorelin’s clinical dose is 2 mg subcutaneously once daily; the 5 mg/mL stock delivers 2 mg per 40 syringe units on a 1 mL insulin syringe.
What the research literature says
Tesamorelin’s FDA-approved clinical dose for HIV-associated lipodystrophy is 2 mg subcutaneously once daily, established across the pivotal Falutz NEJM trial (PMID 18057338) and the pooled phase 3 analysis (PMID 20554713). Most research protocols mirror this dose level. The Tomlinson drug evaluation consolidates the clinical-pharmacology framework (PMID 17086939).
For a 10 mg vial reconstituted with 2 mL of bacteriostatic water (5 mg/mL): a 2 mg dose draws 40 units on an insulin syringe; 1 mg draws 20 units; titration steps in either direction stay within easily-measurable single- and double-digit units. With 1 mL fill (10 mg/mL): 2 mg = 20 units, 1 mg = 10 units. Both fills work; the 2 mL is the typical pick for finer dose-titration resolution.
Tesamorelin’s daily dosing schedule supports a relatively rapid consumption rate from the reconstituted vial — a 10 mg vial at 2 mg/day yields 5 days of dosing — keeping post-reconstitution-stability concerns minimal across typical protocols. The bacteriostatic-water preservative profile supports the multi-week stability framework documented across the lyophilisation literature (PMID 10967427).
Why this matters in research context
Researchers replicating the published HIV-lipodystrophy dose tier (2 mg/day) need volume precision around the 20-40 syringe-unit range — the 2 mL fill is the natural choice. Higher-dose research protocols can use lower reconstitution volumes to keep per-draw syringe volumes practical at the larger dose tier. The dose-titration math is straightforward across the typical research-protocol dose range.
Related compounds
- Tesamorelin 10mg — the compound covered by this answer
Related research questions
References
- Falutz J et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med 2007;357(23):2359-2370. [PMID 18057338]
- Falutz J et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab 2010;95(9):4291-4304. [PMID 20554713]
- Tomlinson B. Drug evaluation: tesamorelin, a synthetic human growth hormone releasing factor. Curr Opin Investig Drugs 2006;7(10):952-961. [PMID 17086939]
Research-questions pages describe research-context use of peptide-research terminology. They do not constitute medical, veterinary, or clinical advice. Tesamorelin is sold strictly as a research-grade reagent for laboratory and bench research applications.